Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,789-1,800 of 4,306
Drug study icon
CompletedEUCTR 2012-003239-47

Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
France, Czechia, Estonia, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2012-002705-21

Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Czechia, Estonia, Poland, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2015-003284-11

Interventional, open-label, flexible-dose, long-term safety study of Lu AF35700 in adult patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Czechia, Estonia, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2014-003569-12

Interventional, randomised, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Czechia, Estonia, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2012-002252-17

Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Czechia, Estonia, Germany, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2017-000788-34

Interventional, randomized, double-blind, active-controlled study of the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom, Bulgaria
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2021-001268-58

Investigation of cellbiological effects of cariprazine in patients with mitochondrial schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Hungary
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Hungary
Sponsor
Semmelweis University, STIA-POC-2020
Condition
Schizophrenia
Drug study icon
TerminatedEUCTR 2012-005661-13

Long-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom
Sponsor
AbbVie Deutschland GmbH & Co. KG
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2018-000178-31

Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Spain
Sponsor
Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA)
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2010-024488-42

Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Denmark
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, AnxietyDrug
Countries
Denmark
Sponsor
Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch
Condition
Schizophrenia, Anxiety
Drug study icon
TerminatedEUCTR 2017-001357-14

Randomized, doubleblind, 4-arms, monocentric, interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Germany
Sponsor
Klinikum der Universität München - AöR verteten durch den Vorstand des Bereiches Humanmedizin
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.